Table 2.
Correlations of Endostatin with Lung Function in Stable COPD and Healthy Control
| Linear Correlation | Partial Correlation | |||
|---|---|---|---|---|
| Stable COPD | HC and Stable COPD | Stable COPD | HC and Stable COPD | |
| FEV1/FVC | r=−0.216, P=0.031 |
r=−0.359, P<0.001 |
r=−0.181 P=0.078 |
r=−0.268 P=0.001 |
| FEV1%pre | rho=−0.260, P=0.009 |
rho=−0.342, P<0.001 |
r=−0.240 P=0.019 |
r=−0.251 P=0.001 |
| MEF75 | rho=−0.275, P=0.007 |
rho=−0.310, P<0.001 |
r=−0.193 P=0.069 |
r=−0.194 P=0.015 |
| MEF50 | rho=−0.257, P=0.010 |
rho=−0.328, P<0.001 |
r=−0.216 P=0.041 |
r=−0.178 P=0.026 |
| MEF25 | rho=−0.184, P=0.067 |
rho=−0.312, P<0.001 |
r=−0.201 P=0.058 |
r=−0.173 P=0.031 |
| MEF75/25 | rho=−0.257, P=0.010 |
rho=−0.305, P<0.001 |
r=−0.249 P=0.018 |
r=−0.161 P=0.045 |
Notes: Serum endostatin was negatively correlated to FEV1/FVC, FEV1%pre, MEF75, MEF50, and MEF75/25 no matter in all the healthy subjects and stable COPD or only the stable COPD group. Endostatin correlated to MEF25 only in the total group of healthy control and stable COPD. After adjusting age, sex, BMI and smoking status, serum endostatin was still negatively with FEV1%pre, MEF50, and MEF75/25 in the stable COPD group. Bold text means significance.
Abbreviations: HC, healthy controls; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MEF75, maximum expiratory flow at 75%; MEF50, maximum expiratory flow at 50%; MEF25, maximum expiratory flow at 25%.